Literature DB >> 27139471

Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii.

Marta Martínez-Guitián1, Juan C Vázquez-Ucha1, Joshua Odingo2, Tanya Parish2, Margarita Poza1, Richard D Waite3, German Bou1, David W Wareham3, Alejandro Beceiro4.   

Abstract

Synergy between colistin and the signal peptidase inhibitor MD3 was tested against isogenic mutants and clinical pairs of Acinetobacter baumannii isolates. Checkerboard assays and growth curves showed synergy against both colistin-susceptible strains (fractional inhibitory concentration index [FICindex] = 0.13 to 0.24) and colistin-resistant strains with mutations in pmrB and phosphoethanolamine modification of lipid A (FICindex = 0.14 to 0.25) but not against colistin-resistant Δlpx strains with loss of lipopolysaccharide (FICindex = 0.75 to 1). A colistin/MD3 combination would need to be targeted to strains with specific colistin resistance mechanisms.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27139471      PMCID： PMC4914650          DOI： 10.1128/AAC.00510-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Signal peptidases.

Authors:  Mark Paetzel; Andrew Karla; Natalie C J Strynadka; Ross E Dalbey
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

2.  Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013.

Authors:  Angeliki Mavroidi; Sofia Likousi; Eleftheria Palla; Maria Katsiari; Zoi Roussou; Asimina Maguina; Evangelia D Platsouka
Journal:  J Med Microbiol       Date:  2015-07-14       Impact factor: 2.472

Review 3.  Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.

Authors:  Marie Kempf; Jean-Marc Rolain
Journal:  Int J Antimicrob Agents       Date:  2011-11-22       Impact factor: 5.283

4.  Synergy assessed by checkerboard. A critical analysis.

Authors:  M H Hsieh; C M Yu; V L Yu; J W Chow
Journal:  Diagn Microbiol Infect Dis       Date:  1993 May-Jun       Impact factor: 2.803

5.  OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.

Authors:  G Bou; A Oliver; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 6.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

7.  Genetic basis of antimicrobial resistance and clonal dynamics of carbapenem-resistant Acinetobacter baumannii sequence type 191 in a Korean hospital.

Authors:  Gati Noble Selasi; Asiimwe Nicholas; Hyejin Jeon; Yoo Chul Lee; Jeong Rae Yoo; Sang Taek Heo; Je Chul Lee
Journal:  Infect Genet Evol       Date:  2015-09-02       Impact factor: 3.342

8.  Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii.

Authors:  Spyros Pournaras; Aggeliki Poulou; Konstantina Dafopoulou; Yassine Nait Chabane; Ioulia Kristo; Demosthenes Makris; Julie Hardouin; Pascal Cosette; Athanassios Tsakris; Emmanuelle Dé
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

9.  Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.

Authors:  Mark D Adams; Gabrielle C Nickel; Saralee Bajaksouzian; Heather Lavender; A Rekha Murthy; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

10.  Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010.

Authors:  Benedikt Huttner; Makoto Jones; Michael A Rubin; Melinda M Neuhauser; Adi Gundlapalli; Matthew Samore
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240
View more
  2 in total

Review 1.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

Review 2.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors:  Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal:  Infect Drug Resist       Date:  2018-08-21       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.